Rural hospitals are facing growing cybersecurity threats and digital demands but often lack the resources to respond — a gap ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product ...

June has seen a slew of executive hires, promotions, exits and layoffs across the healthcare sector. For example, CVS Health ...

Digital health funding held steady in the first half of 2025, with AI-focused startups capturing the majority of capital and driving rapid adoption among providers. The digital health space also saw ...

The Trump administration's healthcare policy changes from the gutting of medical research grants to changes on the CDC vaccine board were the focus of the discussion on the latest episode of the ...

Through a partnership with Nourish, Tia’s members will have access to virtual personalized nutrition guidance that can address a range of needs, such as hormonal balance, fertility, chronic ...

Moving forward, it’s essential for the health tech and medical fields to work together to make remote patient monitoring much more widely available and affordable for everyone across the country ...

Rick Ratliff, a pharmacy industry veteran who was for a time CEO of Surescripts, built a national digital prescription network connecting doctors to pharmacies.

An Insmed drug developed for a serious chronic lung disorder with no FDA-approved therapies handily beat a placebo in a pivotal clinical trial, preliminary results that set the stage for a ...

Many primary care physicians are not participating in value-based payment models. A new study details why and potential solutions.

This week, health data platform Arcadia acquired CareJourney, a health analytics firm designed to facilitate participation in value-based care contracts. The deal combines Arcadia’s data ...

Reacting to an adverse medical event after it has progressed to causing the patient to seek medical help is the least opportune time to address the underlying disease.